Focused On-demand Library for Magnesium transporter protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H0U3

UPID:

MAGT1_HUMAN

Alternative names:

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit MAGT1; Implantation-associated protein

Alternative UPACC:

Q9H0U3; B2RAR4; D3DTE3; Q53G00; Q6P577; Q8NBN6

Background:

Magnesium transporter protein 1 (MAGT1), also known as Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit MAGT1 and Implantation-associated protein, plays a crucial role in the N-glycosylation process. It is an accessory component of the STT3B-containing form of the N-oligosaccharyl transferase (OST) complex, facilitating the transfer of high mannose oligosaccharide to nascent polypeptide chains. Additionally, MAGT1 may be involved in Mg(2+) transport in epithelial cells.

Therapeutic significance:

MAGT1's involvement in diseases such as Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, and Congenital disorder of glycosylation 1CC, underscores its potential as a target for therapeutic intervention. Understanding the role of MAGT1 could open doors to potential therapeutic strategies.